Hubei Biocause Heilen Pharmaceutical Company Description

Hubei Biocause Heilen Pharmaceutical Co., Ltd. engages in the pharmaceutical, chemical, and new energy fuel businesses in China and internationally.

It is involved in the research and development, production, and sales of chemical raw materials and preparations; and provision of contract research and development, and production services.

The company also provides raw material products, including non-steroidal anti-inflammatory raw materials ibuprofen and dexibuprofen, cardiovascular raw materials torsemide and milrinone, anti-tumor raw materials abiraterone acetate, fludarabine phosphate, and granisetron hydrochloride; and preparation products, such as cardiovascular preparations torsemide tablets and non-steroidal anti-inflammatory preparations ibuprofen granules, and other preparations.

In addition, it offers non-anti-inflammatory APIs, cardiovascular, anti-tumor, and anticholinergic APIs and intermediates; antipyretic and analgesic, cardiovascular and anti-infective preparations; and chemicals and formulations.

Hubei Biocause Heilen Pharmaceutical Co., Ltd. was founded in 1995 and is based in Jingmen, China.

Hubei Biocause Heilen Pharmaceutical Co., Ltd.

Country	China
Founded	1995
Industry	Drug Manufacturers - Specialty & Generic
Sector	Healthcare
Employees	952
CEO	Qun Liang

Contact Details

Address: No. 122 Yangwan Road Jingmen, 448000 China
Phone	86 27 6565 1730
Website	biocause.com

Stock Details

Ticker Symbol	301211
Exchange	Shenzhen Stock Exchange
Fiscal Year	January - December
Reporting Currency	CNY
ISIN Number	CNE100005782
SIC Code	2833

Key Executives

Name	Position
Qun Liang	General Manager
Ting Hao Yi	Financial Director
Chunli Yang	Executive Vice President and Director
Jian Gao	Board Secretary
Zhenghua Huang	Deputy General Manager
Weihua Zhu	Deputy General Manager
Kuili Zhang	Deputy General Manager
Qianqian Guan	Deputy General Manager
Chun Hua Quan	Accounting Supervisor